Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis.

Kim KW, Kim HR.

Korean J Intern Med. 2016 Jul;31(4):634-42. doi: 10.3904/kjim.2016.098. Epub 2016 May 12. Review.

2.

A role for innate immunity in the development of hypertension.

Gomolak JR, Didion SP.

Med Hypotheses. 2014 Dec;83(6):640-3. doi: 10.1016/j.mehy.2013.12.027. Epub 2014 Jan 14.

3.

Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Fogal B, Yi T, Wang C, Rao DA, Lebastchi A, Kulkarni S, Tellides G, Pober JS.

J Immunol. 2011 Dec 15;187(12):6268-80. doi: 10.4049/jimmunol.1003774. Epub 2011 Nov 14.

4.

Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis.

Loppnow H, Buerke M, Werdan K, Rose-John S.

J Cell Mol Med. 2011 Mar;15(3):484-500. doi: 10.1111/j.1582-4934.2010.01245.x. Review.

5.

Integrin beta4 attenuates SHP-2 and MAPK signaling and reduces human lung endothelial inflammatory responses.

Chen W, Garcia JG, Jacobson JR.

J Cell Biochem. 2010 Jun 1;110(3):718-24. doi: 10.1002/jcb.22582.

6.

Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures.

Loppnow H, Zhang L, Buerke M, Lautenschläger M, Chen L, Frister A, Schlitt A, Luther T, Song N, Hofmann B, Rose-John S, Silber RE, Müller-Werdan U, Werdan K.

J Cell Mol Med. 2011 Apr;15(4):994-1004. doi: 10.1111/j.1582-4934.2010.01036.x.

7.

S100A12 mediates aortic wall remodeling and aortic aneurysm.

Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, Raman J, McNally EM.

Circ Res. 2010 Jan 8;106(1):145-54. doi: 10.1161/CIRCRESAHA.109.209486. Epub 2009 Oct 29.

8.
9.

Altered interleukin-1 receptor antagonist and interleukin-18 mRNA expression in myocardial tissues of patients with dilatated cardiomyopathy.

Westphal E, Rohrbach S, Buerke M, Behr H, Darmer D, Silber RE, Werdan K, Loppnow H.

Mol Med. 2008 Jan-Feb;14(1-2):55-63.

10.
11.
12.

Human vascular smooth muscle cells express interleukin-1beta-converting enzyme (ICE), but inhibit processing of the interleukin-1beta precursor by ICE.

Schönbeck U, Herzberg M, Petersen A, Wohlenberg C, Gerdes J, Flad HD, Loppnow H.

J Exp Med. 1997 Apr 7;185(7):1287-94.

14.

Binding of lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human cells is mediated by soluble CD14 and LPS-binding protein.

Schletter J, Brade H, Brade L, Krüger C, Loppnow H, Kusumoto S, Rietschel ET, Flad HD, Ulmer AJ.

Infect Immun. 1995 Jul;63(7):2576-80.

15.

Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14.

Loppnow H, Stelter F, Schönbeck U, Schlüter C, Ernst M, Schütt C, Flad HD.

Infect Immun. 1995 Mar;63(3):1020-6.

16.

Anti-CD14 antibodies reduce responses of cultured human endothelial cells to endotoxin.

von Asmuth EJ, Dentener MA, Bazil V, Bouma MG, Leeuwenberg JF, Buurman WA.

Immunology. 1993 Sep;80(1):78-83.

17.
18.

Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS.

Loppnow H, Libby P, Freudenberg M, Krauss JH, Weckesser J, Mayer H.

Infect Immun. 1990 Nov;58(11):3743-50.

Supplemental Content

Support Center